Swiss healthcare firm Roche Diagnostics has launched a new diagnostics legal entity in Nigeria to deepen access to innovative healthcare and improve diagnostics capacity across West Africa.

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...

Peter Ahnesorg is the new head of Roche Hungary’s pharmaceuticals division, replacing Raffaella Claudia Bondi, who led the ...

The European Commission (EC) has approved a label extension for Evrysdi® (risdiplam) to include a new, room-temperature ...

The genomic biomarkers market is experiencing rapid growth, driven by advancements in precision medicine, early disease ...

<li /> 46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with ...

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA ; Evrysdi offers the same efficacy and safety demo ...

The globally active CHEPLAPHARM Group, headquartered in Greifswald, is expanding its management team: Sandra Schroder has been Vice President (VP) Scientific since 1 June 2025. In this newly ...

As an investor who cares about the return in Aussie dollars, this would protect you from an appreciation in the Aussie dollar reducing the value of your foreign holdings. This will usually be ...

The refillable eye implants continuously deliver a customised formulation of a drug over a period of several months. Read ...